Ping An Biomedical Enters into Patent Purchase Agreement with Future Biotechnology Group for Tumor Cell Technologies
Key Highlights
- ➤Ping An Biomedical (PASW) agrees to acquire three tumor-cell patents for US$2.3 million
- ➤Patents cover oncology diagnosis, cell detection, bioengineering, biomarkers, and DNA probes
- ➤Acquisition is not positioned as a near-term revenue driver
- ➤Closing requires completion of registration procedures and applicable approvals
- ➤Ping An Biomedical continues negotiating a proposed strategic investment in Future Biotechnology Group
Expert Statements
Pijun Liu, Chief Executive Officer and Chairman of the Board of Ping An Biomedical Co., Ltd.
“Building a focused healthcare technology IP reserve is a measured step aligned with our long-term view of the medical market”
Pijun Liu, Chief Executive Officer and Chairman of the Board of Ping An Biomedical Co., Ltd.
“Entering into this definitive purchase agreement is a concrete milestone in our healthcare and biomedical strategy. We will actively study how these newly secured technologies can be applied to create tangible value for the Company—whether through internal development, collaboration, or other commercialization pathways. By combining disciplined capital allocation with rigorous compliance oversight, we aim to turn this intellectual property into practical advantages that support the future growth of our healthcare businesses.”
HONG KONG, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced that it has entered into a definitive purchase agreement (the “Agreement”) with Future Biotechnology Group Co., Limited for the acquisition (the “Acquisition”) of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration of US$2.3 million. The Agreement follows the Company’s previously announced letter of intent dated October 22, 2026. The Acquisition is intended to support the Company’s longer-term healthcare and biomedical R&D strategy and to establish a core intellectual property portfolio in oncology and biotechnology.
Execution of the Agreement marks a shift from preliminary intent to a definitive contractual framework in advancing the Company’s healthcare technology. Upon completing the acquisition of the patents spanning oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, the Company seeks to strengthen its position in tumor-related science. Management views these assets as building blocks for a multi-use intellectual property portfolio—supporting proprietary programs where appropriate, while leaving room for co-development or outbound licensing if it will better serve capital efficiency.
Get started
Create a free account to read the full story.